Effect of antiepileptic drug comedication on lamotrigine clearance

被引:54
作者
Weintraub, D
Buchsbaum, R
Resor, SR
Hirsch, LJ
机构
[1] Columbia Univ, Coll Phys & Surg, Columbia Comprehens Epilepsy Ctr, New York, NY 10032 USA
[2] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
[3] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA
关键词
D O I
10.1001/archneur.62.9.1432
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To investigate the effect of antiepileptic drug (AED) comedication, including all newer AEDs, on lamotrigine clearance (CL). Design: We reviewed 570 medical charts of outpatients 12 years and older seen at the Columbia Comprehensive Epilepsy Center who received lamotrigine as monotherapy or adjunctive therapy. We investigated whether a given comedication contributed to the lamotrigine serum concentration. In addition, we examined whether the mean lamotrigine CL during comedication with each AED differed from the lamotrigine CL during monotherapy. Finally, we examined whether individuals had significantly different lamotrigine CLs when taking or not taking a particular comedication. Results: Comedication with phenytoin, carbamazepine, and valproate sodium were the major AED predictors of lamotrigine serum concentration. Comedication regimens with felbamate, oxcarbazepine, and phenobarbital were small but significant predictors. The mean lamotrigine CL was 43.2 mL/h per kilogram of body weight with lamotrigine monotherapy, significantly higher with comedication with phenytoin (101.3 mL/h per kilogram) and carbamazepine (59.5 mL/h per kilogram) and significantly lower with valproate (16.9 mL/h per kilogram). Patients had significantly higher lamotrigine CL when taking phenytoin, carbamazepine, and phenobarbital than when not taking those comedications and had significantly lower lamotrigine CL when taking valproate. The mean lamotrigine CL was significantly lower than that associated with monotherapy in patients comedicated with valproate plus phenytoin (22.0 mL/h per kilogram) but not in patients comedicated with valproate plus carbamazepine (33.3 mL/h per kilogram). No other AEDs affected lamotrigine CL. Conclusion: Phenytoin increases lamotrigine CL by approximately 125%, carbamazepine increases lamotrigine CL by approximately 30% to 50%, and valproate decreases lamotrigine CL by approximately 60%. No newer AED, with the possible exception of oxcarbazepine, has a major impact on lamotrigine CL.
引用
收藏
页码:1432 / 1436
页数:5
相关论文
共 16 条
[1]   Lamotrigine serum concentration-to-dose ratio: Influence of age and concomitant antiepileptic drugs and dosage implications [J].
Armijo, JA ;
Bravo, J ;
Cuadrado, A ;
Herranz, JL .
THERAPEUTIC DRUG MONITORING, 1999, 21 (02) :182-190
[2]   The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessment of correlations with clinical response [J].
Bartoli, A ;
Guerrini, R ;
Belmonte, A ;
Alessandri, MG ;
Gatti, G ;
Perucca, E .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :252-260
[3]   Lack of an effect of topiramate on lamotrigine serum concentrations [J].
Berry, DJ ;
Besag, FMC ;
Pool, F ;
Natarajan, J ;
Doose, D .
EPILEPSIA, 2002, 43 (08) :818-823
[4]   Effect of felbamate on the pharmacokinetics of lamotrigine [J].
Colucci, R ;
Glue, P ;
Holt, B ;
Banfield, C ;
Reidenberg, P ;
Meeahn, JW ;
Pai, S ;
Nomeir, A ;
Lim, J ;
Lin, CC ;
Affrime, MB .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (07) :634-638
[5]   Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients [J].
Doose, DR ;
Brodie, TJ ;
Wilson, TA ;
Chadwick, J ;
Oxbury, J ;
Berry, DJ ;
Schwabe, S ;
Bialer, M .
EPILEPSIA, 2003, 44 (07) :917-922
[6]   Lamotrigine pharmacokinetics in patients receiving felbamate [J].
Gidal, BE ;
Kanner, A ;
Maly, M ;
Rutecki, P ;
Lensmeyer, GL .
EPILEPSY RESEARCH, 1997, 27 (01) :1-5
[7]   Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy [J].
Gidal, BE ;
Anderson, GD ;
Rutecki, PR ;
Shaw, R ;
Lanning, A .
EPILEPSY RESEARCH, 2000, 42 (01) :23-31
[8]   Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy [J].
Gidal, BE ;
Sheth, R ;
Parnell, J ;
Maloney, K ;
Sale, M .
EPILEPSY RESEARCH, 2003, 57 (2-3) :85-93
[9]  
*GLAXOSMITHKLINE, 2004, LAM PACK INS
[10]   Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy [J].
Hirsch, LJ ;
Weintraub, D ;
Buchsbaum, R ;
Spencer, HT ;
Hager, M ;
Strake, T ;
Bazil, CW ;
Adams, DJ ;
Resor, SR ;
Morrell, MJ .
NEUROLOGY, 2004, 63 (06) :1022-1026